Wound closure in epidermolysis bullosa: data from the vehicle arm of the phase 3 ESSENCE Study

• Published in: Orphanet journal of rare diseases Vol. 15; no. 1; pp. 1 - 190
• Main Authors: Murrell, Dedee F., Paller, Amy S., Bodemer, Christine, Browning, John, Nikolic, Milos, Barth, Jay A., Lagast, Hjalmar, Krusinska, Eva, Reha, Allen
• Format: Journal Article
• Language: English
• Published: London BioMed Central 21.07.2020; BMC
• Subjects: Age; Allantoin; Antibiotics; Clinical trials; Demographics; Epidermolysis bullosa; Medical research; Natural history; Pain; Patients; Pruritus; Rare diseases; Skin; Skin diseases; Wound closure; Wounds
• ISSN: 1750-1172; 1750-1172
• DOI: 10.1186/s13023-020-01435-3

Abstract Background Chronic wounds are a fundamental issue for patients with epidermolysis bullosa (EB). Herein, we assess the natural history of wound closure in patients with EB who were randomly assigned to the vehicle-control arm of the multicenter, randomized, double-blind, phase 3 ESSENCE (NCT02384460) trial. Methods ESSENCE was designed to assess the efficacy and safety of a topical cream formulation of 6% allantoin (SD-101 6%) vs vehicle (SD-101 0%) in patients ≥1 month old who had a diagnosis of EB (simplex, recessive dystrophic, or intermediate junctional) and a target wound 10–50 cm 2 present for ≥21 days. Time to complete target wound closure and the proportion of patients with target wound closure over time were analyzed overall and by parameters including patient age and baseline body surface area index (BSAi) of total wound burden (< 5% and ≥ 5%). Changes in BSAi of lesional skin, pain, and itching were also assessed. Results The vehicle-control arm included 87 patients. Mean (standard deviation [SD]) time to target wound closure within 3 months was 53.6 (28.6) days, with a range of 14 to 142 days. The proportion of patients with target wound closure increased over time from 7.1% at day 14 to 53.6% at month 3. Mean (SD) changes from baseline in BSAi of total wound burden and BSAi of lesional skin at month 3 were −2.3% (6.3) and −5.0% (13.5) of total body coverage, respectively. Reductions in pain and itching were observed at day 7 and maintained for 3 months. Faster healing times and a greater proportion of patients with wound closure were observed in patients aged 1 month to < 2 years; those with wounds < 30 days old, and in those with BSAi of total body wound burden < 5%. Conclusions Treatment response observed in the vehicle-control arm of the ESSENCE study was unexpectedly high and may have been due to unforeseen benefits of vehicle or enhanced wound care provided by the clinical trial staff. These observations will help inform the study design of future trials in patients with EB. Trial registration ClinicalTrials.gov , NCT02384460 ; Date of registration: February 13, 2015; First participant enrollment: March 11, 2015.